CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

Drugs for Type 2 Diabetes: Second-Line Therapy Review Update

Last updated: February 7, 2018
Project Number: TR0012-000
Product Line: Therapeutic Review
Result type: Report

For an update on the status of CADTH’s Therapeutic Review of Third-Line Drugs for Type 2 Diabetes, please visit our news section.

CADTH undertook a project to assess the clinical and cost-effectiveness of new drugs for the treatment of patients with type 2 diabetes. These new drugs were in three classes: dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 (GLP-1) analogues, and sodium-glucose cotransporter-2 (SGLT-2) inhibitors. As part of this project, recommendations from the CADTH Canadian Drug Expert Committee (CDEC) were developed.

This project is an update to two large projects on pharmacotherapy for type 2 diabetes completed by CADTH in the past: an evaluation of second- and third-line therapies for type 2 diabetes originally published in 2010 and an update to this evaluation in 2013.

CADTH developed knowledge mobilization tools in support of this project:


What Is the Cost of Diabetes Therapy?

Therapeutic Review
PUBLISHED: August 2018

How Much Do Diabetes Drugs Cost?

Therapeutic Review
PUBLISHED: August 2018

Key Messages Snapshot

Therapeutic Review
PUBLISHED: September 2017

Second-Line Therapy for Type 2 Diabetes

Therapeutic Review
In Brief

CADTH has completed a number of evidence reviews and other projects on the topic of diabetes. Visit our Evidence Bundle on Diabetes Management.